Novo Nordisk
NVO
#22
Rank
S$536.88 B
Marketcap
$115.18
Share price
-17.83%
Change (1 day)
-16.09%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total debt

Total debt on the balance sheet as of September 2024 : S$11.56 Billion

According to Novo Nordisk's latest financial reports the company's total debt is S$11.56 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Novo Nordisk - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$5.28 B6.12%
2022-12-31S$4.97 B-9.23%
2021-12-31S$5.48 B142.17%
2020-12-31S$2.26 B149.91%
2019-12-31S$0.90 B740.65%
2018-12-31S$0.10 B-70.49%
2017-12-31S$0.36 B678.36%
2016-12-31S$46.92 M-78.9%
2015-12-31S$0.22 B43.15%
2014-12-31S$0.15 B208.1%
2013-12-31S$50.43 M-53.48%
2012-12-31S$0.10 B-43.66%
2011-12-31S$0.19 B-62.36%
2010-12-31S$0.51 B36.2%
2009-12-31S$0.37 B-39.79%
2008-12-31S$0.62 B62.13%
2007-12-31S$0.38 B-6.61%
2006-12-31S$0.41 B-41.98%
2005-12-31S$0.70 B40%
2004-12-31S$0.50 B1.82%
2003-12-31S$0.49 B46.9%
2002-12-31S$0.33 B-22.95%
2001-12-31S$0.43 B2.14%
2000-12-31S$0.43 B-8.32%
1999-12-31S$0.46 B-26.73%
1998-12-31S$0.64 B-12.97%
1997-12-31S$0.73 B62.71%
1996-12-31S$0.45 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
S$90.27 B 680.55%๐Ÿ‡บ๐Ÿ‡ธ USA
S$42.17 B 264.63%๐Ÿ‡บ๐Ÿ‡ธ USA
S$69.65 B 502.25%๐Ÿ‡บ๐Ÿ‡ธ USA
S$34.50 B 198.32%๐Ÿ‡ซ๐Ÿ‡ท France